The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer
Background: The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2014-07, Vol.111 (1), p.157-165 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 165 |
|---|---|
| container_issue | 1 |
| container_start_page | 157 |
| container_title | British journal of cancer |
| container_volume | 111 |
| creator | Gujam, F J A Edwards, J Mohammed, Z M A Going, J J McMillan, D C |
| description | Background:
The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and triple negative disease.
Methods:
A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with ⩽50% stroma were classified as the low-TSP group and those with >50% stroma were classified as the high-TSP group.
Results:
A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (
P
=0.035), had more Her-2-positive tumours (
P
=0.029), low-grade tumour inflammatory infiltrate (
P
=0.034), low CD68+macrophage infiltrate (
P |
| doi_str_mv | 10.1038/bjc.2014.279 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4090742</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3366507241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-28ccbe79b36d4ae034a91d50c5d274607034ca1ff975533c2df86059a14dff013</originalsourceid><addsrcrecordid>eNptkU9v1DAQxSMEotvCjTOyhJB6aBbbcWLngoQq_kmVuJSzNXEmG68Se7EdKj4I3xdHu5SCOFn2-83zzLyieMHoltFKven2ZsspE1su20fFhtUVL5ni8nGxoZTKkracnhXnMe7ztaVKPi3OuFBSCEU3xc_bEUnACZL1Lo72QDpMd4iOpCykZfZLIDEFPwM5YDDoEuzwipjJOmv8AdLoJ7-zBiZiRghgEgYbkzWRgOuJX5LxMxLrSGZtLo_kzqaR-OwG3YSkX0zKxV1AiIkYcAbDs-LJAFPE56fzovj64f3t9afy5svHz9fvbkpT1zSVXBnToWy7qukFIK0EtKyvqal7LkVDZX4xwIahlXVdVYb3g2po3QIT_TBQVl0Ub4--h6WbsV-nCzDpQ7AzhB_ag9V_K86Oeue_a5E3KQXPBpcng-C_LRiTnm00OE3g0C9Rs1qIirOGruirf9B93q3L461UJbnirMrU1ZEywccYcLhvhlG95q1z3nrNW-e8M_7y4QD38O-AM_D6BEDMGQ0h79fGP5xqpGBCZa48cjFLbofhQXf_-_gX90zGPQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1543728213</pqid></control><display><type>article</type><title>The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Gujam, F J A ; Edwards, J ; Mohammed, Z M A ; Going, J J ; McMillan, D C</creator><creatorcontrib>Gujam, F J A ; Edwards, J ; Mohammed, Z M A ; Going, J J ; McMillan, D C</creatorcontrib><description>Background:
The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and triple negative disease.
Methods:
A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with ⩽50% stroma were classified as the low-TSP group and those with >50% stroma were classified as the high-TSP group.
Results:
A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (
P
=0.035), had more Her-2-positive tumours (
P
=0.029), low-grade tumour inflammatory infiltrate (
P
=0.034), low CD68+macrophage infiltrate (
P
<0.001), low CD4+ (
P
=0.023) and low CD8+ T-lymphocytes infiltrate (
P
=0.017), tumour recurrence (
P
=0.015) and shorter cancer-specific survival (
P
<0.001). In node-negative patients (
n
=207), high TSP was associated with low CD68+macrophage infiltrate (
P
=0.001), low CD4+ (
P
=0.040) and low CD8+ T-lymphocytes infiltrate (
P
=0.016) and shorter cancer-specific survival (
P
=0.005). In triple negative patients (
n
=151), high TSP was associated with high tumour grade (
P
=<0.001), lymph node positivity (
P
=0.027), low CD68+macrophage infiltrate (
P
=0.011) and shorter cancer-specific survival (
P
=0.035). The 15-year cancer-specific survival rate was 79%
vs
21% in the low-TSP group
vs
high-TSP group. In multivariate survival analysis, a high TSP was associated with reduced cancer-specific survival in the whole cohort (
P
=0.001), node-negative patients (
P
=0.007) and those who received systemic adjuvant therapy (
P
=0.021), independent of other pathological characteristics including host inflammatory response. However, TSP was not an independent prognostic factor for triple negative patients (
P
=0.151).
Conclusions:
A high TSP in primary operable invasive ductal breast cancer was associated with recurrence and poorer long-term survival. The inverse relation with the tumour inflammatory infiltrate highlights the importance of the amount of tumour stroma on immunological response in patients with primary operable ductal breast cancer. Implementing this simple and reproducible parameter in routine pathological examination may help optimise risk stratification in patients with invasive ductal breast cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2014.279</identifier><identifier>PMID: 24874480</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/67/1347 ; 692/700/1750 ; Aged ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Breast cancer ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Breast Neoplasms - therapy ; Cancer Research ; Cancer therapies ; Carcinoma, Ductal, Breast - pathology ; Carcinoma, Ductal, Breast - surgery ; Carcinoma, Ductal, Breast - therapy ; Combined Modality Therapy ; Drug Resistance ; Epidemiology ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Life sciences ; Lymphatic Metastasis ; Lymphatic system ; Mammary gland diseases ; Medical research ; Medical sciences ; Middle Aged ; Molecular Diagnostics ; Molecular Medicine ; Neoplasm Recurrence, Local - pathology ; Oncology ; Stromal Cells - pathology ; Surgery ; Survival Analysis ; Triple Negative Breast Neoplasms - pathology ; Triple Negative Breast Neoplasms - surgery ; Triple Negative Breast Neoplasms - therapy ; Tumor Microenvironment ; Tumors</subject><ispartof>British journal of cancer, 2014-07, Vol.111 (1), p.157-165</ispartof><rights>The Author(s) 2014</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jul 1, 2014</rights><rights>Copyright © 2014 Cancer Research UK 2014 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-28ccbe79b36d4ae034a91d50c5d274607034ca1ff975533c2df86059a14dff013</citedby><cites>FETCH-LOGICAL-c550t-28ccbe79b36d4ae034a91d50c5d274607034ca1ff975533c2df86059a14dff013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090742/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4090742/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=28674148$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24874480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gujam, F J A</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Mohammed, Z M A</creatorcontrib><creatorcontrib>Going, J J</creatorcontrib><creatorcontrib>McMillan, D C</creatorcontrib><title>The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and triple negative disease.
Methods:
A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with ⩽50% stroma were classified as the low-TSP group and those with >50% stroma were classified as the high-TSP group.
Results:
A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (
P
=0.035), had more Her-2-positive tumours (
P
=0.029), low-grade tumour inflammatory infiltrate (
P
=0.034), low CD68+macrophage infiltrate (
P
<0.001), low CD4+ (
P
=0.023) and low CD8+ T-lymphocytes infiltrate (
P
=0.017), tumour recurrence (
P
=0.015) and shorter cancer-specific survival (
P
<0.001). In node-negative patients (
n
=207), high TSP was associated with low CD68+macrophage infiltrate (
P
=0.001), low CD4+ (
P
=0.040) and low CD8+ T-lymphocytes infiltrate (
P
=0.016) and shorter cancer-specific survival (
P
=0.005). In triple negative patients (
n
=151), high TSP was associated with high tumour grade (
P
=<0.001), lymph node positivity (
P
=0.027), low CD68+macrophage infiltrate (
P
=0.011) and shorter cancer-specific survival (
P
=0.035). The 15-year cancer-specific survival rate was 79%
vs
21% in the low-TSP group
vs
high-TSP group. In multivariate survival analysis, a high TSP was associated with reduced cancer-specific survival in the whole cohort (
P
=0.001), node-negative patients (
P
=0.007) and those who received systemic adjuvant therapy (
P
=0.021), independent of other pathological characteristics including host inflammatory response. However, TSP was not an independent prognostic factor for triple negative patients (
P
=0.151).
Conclusions:
A high TSP in primary operable invasive ductal breast cancer was associated with recurrence and poorer long-term survival. The inverse relation with the tumour inflammatory infiltrate highlights the importance of the amount of tumour stroma on immunological response in patients with primary operable ductal breast cancer. Implementing this simple and reproducible parameter in routine pathological examination may help optimise risk stratification in patients with invasive ductal breast cancer.</description><subject>692/699/67/1347</subject><subject>692/700/1750</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Carcinoma, Ductal, Breast - pathology</subject><subject>Carcinoma, Ductal, Breast - surgery</subject><subject>Carcinoma, Ductal, Breast - therapy</subject><subject>Combined Modality Therapy</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Life sciences</subject><subject>Lymphatic Metastasis</subject><subject>Lymphatic system</subject><subject>Mammary gland diseases</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular Diagnostics</subject><subject>Molecular Medicine</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Oncology</subject><subject>Stromal Cells - pathology</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Triple Negative Breast Neoplasms - pathology</subject><subject>Triple Negative Breast Neoplasms - surgery</subject><subject>Triple Negative Breast Neoplasms - therapy</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkU9v1DAQxSMEotvCjTOyhJB6aBbbcWLngoQq_kmVuJSzNXEmG68Se7EdKj4I3xdHu5SCOFn2-83zzLyieMHoltFKven2ZsspE1su20fFhtUVL5ni8nGxoZTKkracnhXnMe7ztaVKPi3OuFBSCEU3xc_bEUnACZL1Lo72QDpMd4iOpCykZfZLIDEFPwM5YDDoEuzwipjJOmv8AdLoJ7-zBiZiRghgEgYbkzWRgOuJX5LxMxLrSGZtLo_kzqaR-OwG3YSkX0zKxV1AiIkYcAbDs-LJAFPE56fzovj64f3t9afy5svHz9fvbkpT1zSVXBnToWy7qukFIK0EtKyvqal7LkVDZX4xwIahlXVdVYb3g2po3QIT_TBQVl0Ub4--h6WbsV-nCzDpQ7AzhB_ag9V_K86Oeue_a5E3KQXPBpcng-C_LRiTnm00OE3g0C9Rs1qIirOGruirf9B93q3L461UJbnirMrU1ZEywccYcLhvhlG95q1z3nrNW-e8M_7y4QD38O-AM_D6BEDMGQ0h79fGP5xqpGBCZa48cjFLbofhQXf_-_gX90zGPQ</recordid><startdate>20140708</startdate><enddate>20140708</enddate><creator>Gujam, F J A</creator><creator>Edwards, J</creator><creator>Mohammed, Z M A</creator><creator>Going, J J</creator><creator>McMillan, D C</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20140708</creationdate><title>The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer</title><author>Gujam, F J A ; Edwards, J ; Mohammed, Z M A ; Going, J J ; McMillan, D C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-28ccbe79b36d4ae034a91d50c5d274607034ca1ff975533c2df86059a14dff013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>692/699/67/1347</topic><topic>692/700/1750</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Carcinoma, Ductal, Breast - pathology</topic><topic>Carcinoma, Ductal, Breast - surgery</topic><topic>Carcinoma, Ductal, Breast - therapy</topic><topic>Combined Modality Therapy</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Life sciences</topic><topic>Lymphatic Metastasis</topic><topic>Lymphatic system</topic><topic>Mammary gland diseases</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular Diagnostics</topic><topic>Molecular Medicine</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Oncology</topic><topic>Stromal Cells - pathology</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Triple Negative Breast Neoplasms - pathology</topic><topic>Triple Negative Breast Neoplasms - surgery</topic><topic>Triple Negative Breast Neoplasms - therapy</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gujam, F J A</creatorcontrib><creatorcontrib>Edwards, J</creatorcontrib><creatorcontrib>Mohammed, Z M A</creatorcontrib><creatorcontrib>Going, J J</creatorcontrib><creatorcontrib>McMillan, D C</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gujam, F J A</au><au>Edwards, J</au><au>Mohammed, Z M A</au><au>Going, J J</au><au>McMillan, D C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2014-07-08</date><risdate>2014</risdate><volume>111</volume><issue>1</issue><spage>157</spage><epage>165</epage><pages>157-165</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
The percentage of tumour stroma (TSP) has recently been reported to be a novel independent predictor of outcome in patients with a variety of common solid organ tumours. The aim of this study was to examine the relationship between TSP, clinicopathological characteristics and outcome in patients with invasive ductal breast cancer, in particular node negative and triple negative disease.
Methods:
A total of 361 patients with primary operable invasive ductal breast cancer were included in this study. The TSP was assessed visually on the haematoxylin and eosin-stained tissue sections. With a cutoff value of 50% TSP, patients with ⩽50% stroma were classified as the low-TSP group and those with >50% stroma were classified as the high-TSP group.
Results:
A total of 109 (30%) patients had high TSP. Patients with high TSP were old age (
P
=0.035), had more Her-2-positive tumours (
P
=0.029), low-grade tumour inflammatory infiltrate (
P
=0.034), low CD68+macrophage infiltrate (
P
<0.001), low CD4+ (
P
=0.023) and low CD8+ T-lymphocytes infiltrate (
P
=0.017), tumour recurrence (
P
=0.015) and shorter cancer-specific survival (
P
<0.001). In node-negative patients (
n
=207), high TSP was associated with low CD68+macrophage infiltrate (
P
=0.001), low CD4+ (
P
=0.040) and low CD8+ T-lymphocytes infiltrate (
P
=0.016) and shorter cancer-specific survival (
P
=0.005). In triple negative patients (
n
=151), high TSP was associated with high tumour grade (
P
=<0.001), lymph node positivity (
P
=0.027), low CD68+macrophage infiltrate (
P
=0.011) and shorter cancer-specific survival (
P
=0.035). The 15-year cancer-specific survival rate was 79%
vs
21% in the low-TSP group
vs
high-TSP group. In multivariate survival analysis, a high TSP was associated with reduced cancer-specific survival in the whole cohort (
P
=0.001), node-negative patients (
P
=0.007) and those who received systemic adjuvant therapy (
P
=0.021), independent of other pathological characteristics including host inflammatory response. However, TSP was not an independent prognostic factor for triple negative patients (
P
=0.151).
Conclusions:
A high TSP in primary operable invasive ductal breast cancer was associated with recurrence and poorer long-term survival. The inverse relation with the tumour inflammatory infiltrate highlights the importance of the amount of tumour stroma on immunological response in patients with primary operable ductal breast cancer. Implementing this simple and reproducible parameter in routine pathological examination may help optimise risk stratification in patients with invasive ductal breast cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>24874480</pmid><doi>10.1038/bjc.2014.279</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2014-07, Vol.111 (1), p.157-165 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4090742 |
| source | MEDLINE; Springer Nature - Complete Springer Journals; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | 692/699/67/1347 692/700/1750 Aged Biological and medical sciences Biomedical and Life Sciences Biomedicine Breast cancer Breast Neoplasms - pathology Breast Neoplasms - surgery Breast Neoplasms - therapy Cancer Research Cancer therapies Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - surgery Carcinoma, Ductal, Breast - therapy Combined Modality Therapy Drug Resistance Epidemiology Female Gynecology. Andrology. Obstetrics Humans Life sciences Lymphatic Metastasis Lymphatic system Mammary gland diseases Medical research Medical sciences Middle Aged Molecular Diagnostics Molecular Medicine Neoplasm Recurrence, Local - pathology Oncology Stromal Cells - pathology Surgery Survival Analysis Triple Negative Breast Neoplasms - pathology Triple Negative Breast Neoplasms - surgery Triple Negative Breast Neoplasms - therapy Tumor Microenvironment Tumors |
| title | The relationship between the tumour stroma percentage, clinicopathological characteristics and outcome in patients with operable ductal breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T13%3A43%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20relationship%20between%20the%20tumour%20stroma%20percentage,%20clinicopathological%20characteristics%20and%20outcome%20in%20patients%20with%20operable%20ductal%20breast%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Gujam,%20F%20J%20A&rft.date=2014-07-08&rft.volume=111&rft.issue=1&rft.spage=157&rft.epage=165&rft.pages=157-165&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2014.279&rft_dat=%3Cproquest_pubme%3E3366507241%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1543728213&rft_id=info:pmid/24874480&rfr_iscdi=true |